The stock has a 36-month beta value of 0.26. Opinions on the stock are mixed, with 13 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RARE is 88.38M, and at present, short sellers hold a 6.88% of that float. On June 27, 2025, the average trading volume of RARE was 1.01M shares.
RARE) stock’s latest price update
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)’s stock price has plunge by -2.65relation to previous closing price of 37.12. Nevertheless, the company has seen a -2.71% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-27 that Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for GTX-102 (apazunersen) as a treatment for Angelman syndrome.
RARE’s Market Performance
Ultragenyx Pharmaceutical Inc (RARE) has seen a -2.71% fall in stock performance for the week, with a 5.20% gain in the past month and a -7.08% plunge in the past quarter. The volatility ratio for the week is 3.72%, and the volatility levels for the past 30 days are at 4.06% for RARE. The simple moving average for the past 20 days is -2.21% for RARE’s stock, with a -17.20% simple moving average for the past 200 days.
Analysts’ Opinion of RARE
Goldman, on the other hand, stated in their research note that they expect to see RARE reach a price target of $67, previously predicting the price at $56. The rating they have provided for RARE stocks is “Buy” according to the report published on June 06th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to RARE, setting the target price at $77 in the report published on April 22nd of the previous year.
RARE Trading at -1.11% from the 50-Day Moving Average
After a stumble in the market that brought RARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.14% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RARE starting from Sanders Corazon (Corsee) D., who sale 2,405 shares at the price of $37.39 back on Jun 20 ’25. After this action, Sanders Corazon (Corsee) D. now owns 15,344 shares of Ultragenyx Pharmaceutical Inc, valued at $89,923 using the latest closing price.
Stock Fundamentals for RARE
Current profitability levels for the company are sitting at:
- -0.87 for the present operating margin
- 0.84 for the gross margin
The net margin for Ultragenyx Pharmaceutical Inc stands at -0.93. The total capital return value is set at -0.5. Equity return is now at value -386.33, with -41.97 for asset returns.
Based on Ultragenyx Pharmaceutical Inc (RARE), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -10.19. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -8.35.
Currently, EBITDA for the company is -469.0 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 5.72. The receivables turnover for the company is 5.98for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.40.
Conclusion
To sum up, Ultragenyx Pharmaceutical Inc (RARE) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
